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PMy third question relates to the clinical indications for the
device. There is a broad spectrum of patients with type IIIb MR
with regard to the severity of mitral regurgitation and the degree of
left ventricular dilatation. Which patients within this spectrum do
you feel are likely to have a successful, durable outcome with this
device? Specifically, do you believe that it will work as sole
therapy for patients with severe MR and dilated ventricles or do
you see it as an adjunct to annuloplasty in these patients?
Dr McCarthy. First, we assess carefully all of the changes that
we see regarding durability. One explanation for some of the
differences in measurements—which, by the way, were only about
3 mm—is that some of those measurements were made in the acute
setting with the chest open, versus later measurements with the
chest closed. So there are certainly differences in loading condi-
tions. Also, measurements are influenced by the difference in echo
techniques in that the measurement of the annular area was by
short axis, the measurement of the septolateral by long axis, and
the commissure-to-commissure measurement by 2-chamber views.
So it is hard in 2-D echoes to really recreate the total annular areaThe Journal of Thoracicent views. Furthermore, this is a pacing model of heart failure that
we had developed a few years ago, and there is ongoing pacing at
a rate of 190 beats per minute. So we expect that there would be
some continued remodeling during that time, which may account
for some of the small changes. Nevertheless, durability is the most
important issue for the clinical trials.
In terms of the technique, I completely agree that anatomic
measurements, including coaptation depth and length, would prob-
ably be a much more accurate way to judge how to place the
device than merely by interpreting color Doppler echo. This is
certainly something that will be looked at carefully in the clinical
cases.
In terms of the clinical indications, I don’t know yet exactly
what role this is going to have. Coapsys just recently began a
randomized clinical trial in the United States with groups of
patients undergoing coronary artery bypass grafting (CABG) with
ring annuloplasty, patients undergoing CABG alone, and CABG
with the Coapsys device. So we will be looking at how this holds
up in patients with ischemic cardiomyopathy and then we canand correlate it to the other 2 measurements because of the differ- determine the proper role for Coapsys.and Cardiovascular Surgery ● Volume 127, Number 4 1077
